Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 124.95 USD -0.04%
Market Cap: 12.7B USD
Have any thoughts about
Neurocrine Biosciences Inc?
Write Note

Relative Value

The Relative Value of one NBIX stock under the Base Case scenario is 132.63 USD. Compared to the current market price of 124.95 USD, Neurocrine Biosciences Inc is Undervalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NBIX Relative Value
Base Case
132.63 USD
Undervaluation 6%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
53
Median 3Y
6.9
Median 5Y
7.6
Industry
7.7
Forward
5.3
vs History
76
vs Industry
4
Median 3Y
60.2
Median 5Y
57.4
Industry
22.7
Forward
30.6
vs History
85
vs Industry
8
Median 3Y
31.5
Median 5Y
34
Industry
21.6
vs History
19
vs Industry
7
Median 3Y
38.7
Median 5Y
39.8
Industry
25.2
vs History
95
vs Industry
15
Median 3Y
5.9
Median 5Y
6.6
Industry
2.5
vs History
93
vs Industry
48
Median 3Y
6.4
Median 5Y
7.1
Industry
7.7
Forward
4.8
vs History
93
vs Industry
46
Median 3Y
6.5
Median 5Y
7.2
Industry
9
vs History
95
vs Industry
4
Median 3Y
31.4
Median 5Y
32.2
Industry
4.2
Forward
16.5
vs History
95
vs Industry
4
Median 3Y
33.4
Median 5Y
33.7
Industry
4.1
Forward
18.7
vs History
87
vs Industry
8
Median 3Y
28.6
Median 5Y
31.3
Industry
5.7
vs History
84
vs Industry
6
Median 3Y
30.8
Median 5Y
33.1
Industry
3.6
vs History
95
vs Industry
27
Median 3Y
7.4
Median 5Y
9.2
Industry
4.6

Multiples Across Competitors

NBIX Competitors Multiples
Neurocrine Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Neurocrine Biosciences Inc
NASDAQ:NBIX
12.7B USD 5.7 32.8 18.7 19.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.4B USD 5.7 61.9 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 11 -243 24.2 25.5
US
Gilead Sciences Inc
NASDAQ:GILD
112.5B USD 4 892.3 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.3B USD 6 17.7 16.1 17.9
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
P/E Multiple
Earnings Growth
US
Neurocrine Biosciences Inc
NASDAQ:NBIX
Average P/E: 179.2
32.8
261%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -243
42%
US
Gilead Sciences Inc
NASDAQ:GILD
892.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Neurocrine Biosciences Inc
NASDAQ:NBIX
Average EV/EBITDA: 17.4
18.7
203%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
EV/EBIT Multiple
EBIT Growth
US
Neurocrine Biosciences Inc
NASDAQ:NBIX
Average EV/EBIT: 22.1
19.5
213%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A

See Also

Discover More
Back to Top